Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab plus /- chemotherapy in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Ricciuti, Biagio
Champagne, Christine
Jones, Greg
Lazarus, Tadd Scott
Adeni, Anika E.
Cheng, Michael L.
Oxnard, Geoffrey R.
Awad, Mark M.
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Inivata, Cambridge, England
[4] Inivata Inc, Austin, TX USA
[5] Massachusetts Gen Hosp, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3518
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Health outcomes of pembrolizumab plus chemotherapy in non-small cell lung cancer
    Marin Pozo, Juan Francisco
    Cao Vina, Vanesa
    Plaza Arbeo, Ainoa
    Morales Rivero, Begona
    Ortega Granados, Ana Laura
    Lopez Lopez, Jose Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
    Kyoichi Kaira
    Ou Yamaguchi
    Tomonori Kawasaki
    Kousuke Hashimoto
    Yu Miura
    Ayako Shiono
    Atsuto Mouri
    Hisao Imai
    Kunihiko Kobayashi
    Masanori Yasuda
    Hiroshi Kagamu
    Discover Oncology, 14
  • [43] Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer
    Kaira, Kyoichi
    Yamaguchi, Ou
    Kawasaki, Tomonori
    Hashimoto, Kousuke
    Miura, Yu
    Shiono, Ayako
    Mouri, Atsuto
    Imai, Hisao
    Kobayashi, Kunihiko
    Yasuda, Masanori
    Kagamu, Hiroshi
    DISCOVER ONCOLOGY, 2023, 14 (01)
  • [44] Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer
    Johnson, Martin
    Traynor, Carlos Serra
    Vishwanathan, Karthick
    Overend, Philip
    Hartmaier, Ryan
    Markovets, Aleksandra
    Chmielecki, Juliann
    Mugundu, Ganesh M.
    Barrett, J. Carl
    Tomkinson, Helen
    Ramalingam, Suresh S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (02) : 349 - 360
  • [45] Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)
    Wang, J.
    Lu, S.
    Hu, C.
    Sun, Y.
    Yang, K.
    Chen, M.
    Zhao, J.
    Yu, G.
    Zhou, X.
    Feng, G.
    Pan, Y.
    Yu, Y.
    Zhang, J.
    Liang, L.
    Lin, X.
    Wu, X.
    Cui, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S817 - S817
  • [46] First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
    Andric, Z. G.
    Galffy, G.
    Cobo Dols, M.
    Szima, B.
    Stojanovic, G.
    Petrovic, M. D.
    Felip Font, E.
    Vicente Baz, D.
    Ponce Aix, S.
    Juan-Vidal, O.
    Tehenes, S.
    Szalai, Z.
    Losonczy, G.
    Calles Blanco, A.
    Bernabe, R.
    Duecker, K.
    Zhou, D.
    Schroeder, A.
    Guezel, G.
    Ciardiello, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S753 - S754
  • [47] Oxaliplatin and docetaxel as first line chemotherapy for patients with non-small cell lung cancer (NSCLC).
    Santos, ES
    Raez, LE
    Rocha-Lima, C
    Tolba, K
    Negret, L
    Farfan, N
    Decesare, T
    Lopes, G
    Rosado, MF
    Wu, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 687S - 687S
  • [48] Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
    Wang, J.
    Lu, S.
    Hu, C.
    Sun, Y.
    Yang, K.
    Chen, M.
    Zhao, J.
    Yu, G.
    Zhou, X.
    Feng, G.
    Pan, Y.
    Yu, Y.
    Zhang, J.
    Liang, L.
    Lin, X.
    Cui, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S3 - S3
  • [49] Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation from Circulating Tumor DNA
    Park, C.
    Cho, H.
    Choi, Y. D.
    Oh, I.
    Kim, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S492 - S492
  • [50] An Indirect Comparison Between Nivolumab plus Ipilimumab plus Two Cycles of Chemotherapy vs. Pembrolizumab plus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer
    Jiang, Panpan
    Mao, Ziyang
    Wang, Qinyang
    Jia, Xiaohui
    Geng, Luying
    Xu, Hong
    Jiang, Lili
    Yang, Chengcheng
    Jiao, Min
    Guo, Hui
    FRONTIERS IN ONCOLOGY, 2021, 11
12345